A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis

This study will evaluate the safety and efficacy of Relamorelin compared to placebo in
patients with diabetic gastroparesis. Patients will report daily severity scores of their
diabetic gastroparesis symptoms.

Eligibility Criteria

Inclusion Criteria:

- Diagnosis of Type 1 or Type 2 diabetes mellitus

- Meet the per protocol criteria of diabetic gastroparesis

- Compliance with diary

- Compliance with the per protocol study treatment dosing instructions

Exclusion Criteria:

- Currently receiving nutrition intravenously, by nasogastric tube, or other feeding
tube

- History of an eating disorder (eg, anorexia nervosa, binge-eating, bulimia) in the
past 5 years

- Diagnosis of Celiac Disease

- History of gastrointestinal disorders that may be similar to gastroparesis

Principal Investigator

Tuba Esfandyari, MD

Study Contact

Clinical Trials Registry Team, IR-CTRegistration@allergan.com, 877‐277‐8566

Estimated Completion Date

Sunday, July 5, 2020

ClinicalTrials.gov #

NCT03285308
03/26/2018